Analysis of CBX1's Role in Cancer
Start Date
April 2024
Location
MCD 130
Abstract
CBX1 is a coding gene that encodes a highly conserved non-histone protein. CBX1 functions in embryonic development, stem cell maintenance, and regulation of cell proliferation and apoptosis. Mutations in this gene disrupt transcriptional regulation by giving DNA polymerase inappropriate access to DNA. Data from the Catalogue of Somatic Mutations in Cancer (COSMIC) was utilized for analysis after parsing for patient age. Relevant clinical data was extracted for analysis focusing on mutation type, cancer type, primary histology, and coding vs noncoding sequences. To determine the significance of CBX1 gene mutations, Cancer-Related Analysis of Variants Toolkit (CRAVAT) software was used. Clustal Omega was used to perform multiple sequence alignments to identify homologous sequences. Statistical analysis and graph generation was performed using GraphPad Prism. The results showed that there were more mutations in noncoding regions compared to coding regions. The most common mutation type was missense substitutions identified in the endometrium. The mutations in CBX1 were commonly found in carcinomas. Through genome analysis, CBX1 expression was more prevalent in the brain compared to the endometrium. Mean age at time of analysis were observed between patients 55+ and 54-. A chi-squared analysis showed no significance between the non-conserved regions and the conserved regions. In the significant mutations multiple sequence alignment, clustered functional domains were found in the conserved region. The main significant mutation was a change from glutamic acid to lysine. Evidence of upregulation in CBX1 has been found in oncogenes across various malignant tumors and cancer types.
Analysis of CBX1's Role in Cancer
MCD 130
CBX1 is a coding gene that encodes a highly conserved non-histone protein. CBX1 functions in embryonic development, stem cell maintenance, and regulation of cell proliferation and apoptosis. Mutations in this gene disrupt transcriptional regulation by giving DNA polymerase inappropriate access to DNA. Data from the Catalogue of Somatic Mutations in Cancer (COSMIC) was utilized for analysis after parsing for patient age. Relevant clinical data was extracted for analysis focusing on mutation type, cancer type, primary histology, and coding vs noncoding sequences. To determine the significance of CBX1 gene mutations, Cancer-Related Analysis of Variants Toolkit (CRAVAT) software was used. Clustal Omega was used to perform multiple sequence alignments to identify homologous sequences. Statistical analysis and graph generation was performed using GraphPad Prism. The results showed that there were more mutations in noncoding regions compared to coding regions. The most common mutation type was missense substitutions identified in the endometrium. The mutations in CBX1 were commonly found in carcinomas. Through genome analysis, CBX1 expression was more prevalent in the brain compared to the endometrium. Mean age at time of analysis were observed between patients 55+ and 54-. A chi-squared analysis showed no significance between the non-conserved regions and the conserved regions. In the significant mutations multiple sequence alignment, clustered functional domains were found in the conserved region. The main significant mutation was a change from glutamic acid to lysine. Evidence of upregulation in CBX1 has been found in oncogenes across various malignant tumors and cancer types.
